Evidence map›Paper›PMID 40352930›Full record

ArticleFrontiers in immunology2025

Inga Hochnadel, Lisa Hoenicke, Nataliia Petriv, Huizhen Suo, Lothar Groebe, Chantal Olijnik, Nina Bondarenko, Juan C Alfonso, Michael Jarek, Ruibing Shi and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Inga Hochnadel *Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Lisa Hoenicke *Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Nataliia Petriv *Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Huizhen SuoDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Lothar GroebeExperimental Immunology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.
Chantal OlijnikDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Nina BondarenkoDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Juan C AlfonsoDepartment of Systems Immunology, Technical University Braunschweig and HZI, Braunschweig, Germany.
Michael JarekGenome Analytics, HZI, Braunschweig, Germany.
Ruibing ShiBiostatistics Research Group, HZI, Braunschweig, Germany.
Andreas JeronImmune Regulation Group, HZI, Braunschweig, Germany.
Kai TimrottDepartment of General, Visceral and Transplant Surgery, MHH, Hannover, Germany.
Tatjana HirschImmune Regulation Group, HZI, Braunschweig, Germany.
Nils JedickeDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Dunja BruderImmune Regulation Group, HZI, Braunschweig, Germany.
Frank KlawonnBiostatistics Research Group, HZI, Braunschweig, Germany.
Ralf LichtinghagenDepartment of Clinical Chemistry, MHH, Hannover, Germany.
Robert GeffersGenome Analytics, HZI, Braunschweig, Germany.
Henrike LenzenDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Michael P MannsDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
Tetyana YevsaDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) represents the third deadliest cancer worldwide with limited treatment options. Immune checkpoint inhibitors (ICIs) have revolutionized HCC therapy, but immune suppression within the tumor microenvironment remains a major challenge. Therefore, in this study, we aimed to define novel ICI molecules arising on T cells during aggressive HCC development. Methods: Using autochthonous HCC models, we performed microarray analyses followed by Results: We identified neutrophilic granule protein ( Conclusion: The obtained results pave the way for the use of the newly defined ICI molecules

Indexed as

Calgranulin ACarcinoma, HepatocellularCD8-Positive T-LymphocytesLiver NeoplasmsAnimalsCD4-Positive T-LymphocytesCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsMaleMiceRNA InterferenceTumor MicroenvironmentCalgranulin AImmune Checkpoint Inhibitorshepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyRNA interference screenT lymphocytes

Identifiers

PMID40352930
PMCPMC12061932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.